nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2004

Biological characterisation of breast cancer by means of PET

verfasst von: Andreas K. Buck, Holger Schirrmeister, Torsten Mattfeldt, Sven N. Reske

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is associated with increased glucose consumption and can therefore be visualised with the glucose analogue [¹⁸F]2-deoxy-2-fluoro-d-glucose (FDG) and positron emission tomography (PET). FDG uptake in the primary tumour can vary substantially, and specific tumour characteristics have been demonstrated to determine the degree of glucose metabolism. Factors with a major influence on FDG uptake in breast cancer comprise expression of glucose transporter Glut-1 and hexokinase I, number of viable tumour cells per volume, histological subtype, tumour grading, microvessel density and proliferative activity. Recently, an association between high FDG uptake and a worse prognosis was suggested. Several studies have been performed correlating FDG uptake with a variety of prognostic and molecular biomarkers as well as parameters predicting tumour response to therapy. However, a correlation with important clinical prognostic markers such as axillary lymph node status and size of the primary tumour, expression of oestrogen and progesterone receptors, proto-oncogene c-erbB-2 or VEGF could not be demonstrated. The lack of correlation with important markers of prognosis does not suggest that FDG uptake might be used as a prognostic criterion in breast cancer. Innovative radiotracers for specific imaging of tumoural perfusion ([¹⁵O]H₂O), hormone receptor expression ([¹⁸F]FES), protein synthesis ([¹¹C]methionine), proliferation rate ([¹⁸F]FLT) or bone mineralisation ([¹⁸F]fluoride) may provide additional information compared with that provided by FDG PET.

Avril N, Dose J, Janicke F. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14:1848–1857.PubMed

Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, Schwaiger M. Glucose metabolism of breast cancer assessed by¹⁸F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9–16.PubMed

Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Kreienberg R, Buck A, Reske SN. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351–358.PubMed

Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev 2001; 27:295–304.CrossRefPubMed

Warburg O, Posener K, Negelein E. The metabolism of cancer cells. Biochem Zschr 1924; 152:129–169.

Dehdashti F, Mortimer J, Siegel B. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36:1766–1774.PubMed

Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414–419.PubMed

Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36:1854–1861.PubMed

Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20:379–387.PubMed

10.

Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927–1932.PubMed

11.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed

12.

Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T. Characterization of¹⁸F-FDG uptake in human endothelial cells in vitro. J Nucl Med 2004; 45:455–460.PubMed

13.

Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38:1344–1348.PubMed

14.

Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72:2979–2985.PubMed

15.

Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 1996; 56:2468–2471.PubMed

16.

Caraco C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of [¹⁸F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000; 275:18489–18494.CrossRefPubMed

17.

Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37:1042–1047.PubMed

18.

Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999; 59:4709–4714.PubMed

19.

Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207:767–774.PubMed

20.

Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276:43407–43412.CrossRefPubMed

21.

Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002; 29:443–453.CrossRefPubMed

22.

Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36:1625–1632.PubMed

23.

Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001; 42:170–175.PubMed

24.

Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001; 3:80–87.CrossRefPubMed

25.

Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93:309–314.CrossRefPubMed

26.

Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 2000; 59:47–53.CrossRefPubMed

27.

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353–364.PubMed

28.

Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[¹⁸F]-d-glucose. Cancer 1998; 82:2227–2234.PubMed

29.

Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86:1566–1577.CrossRefPubMed

30.

Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1–8.PubMed

31.

Masood S, Chiao J. Pathology of breast cancer. In: Taillefer R, Khalkhali I, Waxman AD, Biersack HJ, eds. Radionuclide imaging of the breast. New York: Dekker, 1998.

32.

Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317–1323.CrossRefPubMed

33.

Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG, Bombardieri E. Association between [¹⁸F]fluorodeoxy-glucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998; 25:1429–1434.PubMed

34.

Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495–3502.PubMed

35.

Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6:375–392.CrossRefPubMed

36.

Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001; 19:972–979.PubMed

37.

MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, deMascarel I, Coindre J. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MIB1, pS2 and GSTπ. Br J Cancer 1996; 74:1458–1465.PubMed

38.

Dettmar P, Harbeck N, Thommsen C, Pache L, Ziffer P, Fizi K, Janicke F, Nathrath W, Schmitt M, Graeff H, Hofler H. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 1997; 75:1525–1533.PubMed

39.

Gebauer G, Fehm T, Merkle E, Jaeger W, Mitze M. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients—prognostic relevance after 10 years. Anticancer Res 2003; 23:4319–4324.PubMed

40.

den Bakker MA, van Weeszenberg A, de Kanter AY, Beverdam FH, Pritchard C, van der Kwast TH, Menke-Pluymers M. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol 2002; 55:932–935.CrossRefPubMed

41.

Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET. Radiology 1993; 187:743–750.PubMed

42.

Crowe JP Jr, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1:132–140.PubMed

43.

Keshgegian A, Cnaan A. Proliferation markers in breast carcinoma. Am J Cell Pathol 1995; 5:42–49.

44.

Barnard NJ, Hall PA, Lemoine NR. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152:287–295.PubMed

45.

Barbareschi M. Prognostic value of immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9,000 patients. Appl Immunohistochem 1996; 4:106–116.

46.

Alred D, Clatk G, Elledge R. Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200–206.PubMed

47.

Overgaard J, Yilmaz M, Guldberg P, Hansen L, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000; 39:327–333.PubMed

48.

Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000; 18:2948–2956.PubMed

49.

Rudolph P, Alm P, Olsson H, Heidebrecht H, Ferno M, Baldetorp B, Parwaresch R. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001; 32:311–319.PubMed

50.

Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984; 1:131–134.PubMed

51.

Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992; 52:1592–1597.PubMed

52.

Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003; 30:274–280.PubMed

53.

McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of 16 alpha-[¹⁸F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32:1526–1531.PubMed

54.

Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19:2797–2803.PubMed

55.

Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of¹¹C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991; 64:1121–1124.PubMed

56.

Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13:1470–1477.PubMed

57.

Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B. 3-deoxy-3-[¹⁸F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331–3334.PubMed

58.

Cobben DC, van der Laan BF, Hoekstra HJ, Jager PL, Willemsen AT, Vaalburg W, Suurmeijer AJ, Elsinga PH. Detection of mammary, laryngeal and soft tissue tumors with FLT-PET. J Nucl Med 2002; 43:P278.

59.

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61–66.PubMed

60.

Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, Messer P, Nussle K, Elsner K, Glatting G, Trager H, Neumaier B, Diederichs C, Reske SN. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381–2389.PubMed

61.

Yamashita K, Koyama H, Inaji H. Prognostic significance of bone metastasis from breast cancer. Clin Orthop Related Res 1995; 312:89–94.

62.

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375–3379.PubMed

Titel: Biological characterisation of breast cancer by means of PET
verfasst von: Andreas K. Buck
Holger Schirrmeister
Torsten Mattfeldt
Sven N. Reske
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1529-6

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2004

Advantages and limitations of FDG PET in the follow-up of breast cancer

153Sm-EDTMP for bone pain palliation in skeletal metastases

Breast scintigraphy today: indications and limitations

99mTc-MIBI in the evaluation of breast cancer biology

FDG-PET for axillary lymph node staging in primary breast cancer

FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer